548 related articles for article (PubMed ID: 12579284)
1. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
2. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
3. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
4. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
Hritz I; Gyorffy H; Molnar B; Lakatos G; Sipos F; Pregun I; Juhasz M; Pronai L; Schaff Z; Tulassay Z; Herszenyi L
Pathol Oncol Res; 2009 Jun; 15(2):183-92. PubMed ID: 18752044
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.
Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH
Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717
[TBL] [Abstract][Full Text] [Related]
6. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea].
Kim CW; Lee BI; Kim BW; Kim JI; Park SH; Kim JK; Han SW; Jung IS; Sun HS; Lee AW; Lee KY
Korean J Gastroenterol; 2005 Sep; 46(3):189-95. PubMed ID: 16179838
[TBL] [Abstract][Full Text] [Related]
8. ErbB2 without erbB3 expression in metaplastic columnar epithelium of Barrett's esophagus.
Nishigaki H; Wada K; Tatsuguchi A; Sueoka N; Futagami S; Gudis K; Miyake K; Tsukui T; Sakamoto C
Digestion; 2004; 70(2):95-102. PubMed ID: 15375338
[TBL] [Abstract][Full Text] [Related]
9. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
10. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
13. P53 and Ki-67 overexpression in gastroesophageal reflux disease--Barrett's esophagus and adenocarcinoma sequence.
Binato M; Gurski RR; Fagundes RB; Meurer L; Edelweiss MI
Dis Esophagus; 2009; 22(7):588-95. PubMed ID: 19302208
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
15. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.
Hong MK; Laskin WB; Herman BE; Johnston MH; Vargo JJ; Steinberg SM; Allegra CJ; Johnston PG
Cancer; 1995 Jan; 75(2):423-9. PubMed ID: 7812911
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model.
Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S
J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062
[TBL] [Abstract][Full Text] [Related]
17. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and immunohistochemical study of cancer arising from Barrett's esophagus.
Noguchi T; Takeno S; Uchida Y; Shimoda H; Daa T; Yokoyama S
Oncol Rep; 1999; 6(6):1293-7. PubMed ID: 10523700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]